Learn More-External Link
Trending at Lumira Ventures
Pharmasset Inc files for $100 mln debt, stock offer
Learn More-External Link
Argos Therapeutics Presents Data on the Mechanism of Immunosuppression by…
Learn More-External Link
TransMolecular starts new Phase 1 trial of brain cancer drug
Learn More-External Link
Pharmasset Selects New Development Candidate for Hepatitis C
Learn More-External Link
Argos Therapeutics Discusses Novel Solutions for Automated Immunotherapy…
Learn More-External Link
BD purchases cell sorting tool firm
Learn More-External Link
INTERVIEW – Mako Surgical sees no impact from credit crunch
Learn More-External Link
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Learn More-External Link
Cardiac Dimensions(R) Inc. Announces First Implant Of CARILLON(TM) Device In Its TITAN(TM) Study
Learn More-External Link
Argos Starts Phase II Proof-of-Concept Trial for HIV Drug
Learn More-External Link
Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance
Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease First-in-Class Compound Designed to Improve Clinical Outcomes During Treatment of a Heart Attack Princeton, NJ, and South San Francisco, CA – May 13, 2008 …
Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial…
Learn More-External Link
Cardiac Dimensions® Inc. Announces Completion of European AMAEDUS™ Study
Published: Oct 02, 2007 KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions® Inc., a developer of devices to treat heart failure and related conditions, today announced that it has completed enrollment in the AMADEUS™ trial. AMADEUS™ (Carillon Mitral Annuloplasty Device European Union Study), a …
Alexza Completes Enrollment in Phase 2a Clinical Trial with AZ-002 (Staccato® Alprazolam) in Panic D
Alexza Completes Enrollment in Phase 2a Clinical Trial with AZ-002 (Staccato® Alprazolam) in Panic Disorder Patients Mountain View, California – April 30, 2008 – Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed the enrollment in its Phase …